Core Viewpoint - The company, China National Pharmaceutical Group Modern (600420), has received approval from the National Medical Products Administration for the marketing application of the raw material drug, Pentazocine Hydrochloride, which is widely used for pre-anesthetic medication and emergency treatment of organophosphate poisoning [1] Group 1 - The approval allows the company to market Pentazocine Hydrochloride, expanding its product offerings in the pharmaceutical sector [1] - The total research and development investment for this project amounts to approximately RMB 4.805 million [1] - The current approval is not expected to have a significant impact on the company's operating performance for the period [1]